MSH Release Inhibiting Factor, amide

Research use only, not for human use.

MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).

MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).

MIF-1 (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials.

MIF-1 (Melanostatin, 1 mg/kg; i.p.; once, for 1 hour; male Wistar rats) modulates the analgesic effects and stress-induced analgesia (SIA).MIF-1 (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats.Animal Model:Male Wistar rats Dosage:1 mg/kg Administration:Intraperitoneal injection; once, for 1 hour Result:Decreased the analgesic effect. Increased the pain threshold for at least 1 h.Animal Model:Sprague-Dawley rats Dosage:1 mg/kg Administration:Intraperitoneal injection; daily, for 8 weeks Result:Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol treatment.

———

Others

Other Targets

———

———

———

2002-44-0

284.36

C13H24N4O3

>98% (HPLC)

———

———

——

(-20℃)

With Ice Pack

≥ 2 years